Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Zoetis Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income attributable to Zoetis Inc.
Net loss attributable to noncontrolling interests
Net noncash charges
Other changes in assets and liabilities, net of acquisitions and divestitures
Net cash provided by operating activities
Cash paid during the period for interest, net of capitalized interest, net of tax1
Capitalized interest expense, net of tax2
Capital expenditures
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Operating Activities Cash Flow
The net cash provided by operating activities exhibited a generally positive trend over the five-year period. Beginning at $1,795 million in 2019, it increased to $2,126 million in 2020 and continued to rise slightly to $2,213 million in 2021. However, in 2022, a decline was observed, with net cash decreasing to $1,912 million. This downturn was short-lived as the figure rebounded in 2023, reaching the highest level within the period at $2,353 million. Overall, the operating cash flow increased by approximately 31% from 2019 to 2023.
Free Cash Flow to the Firm (FCFF)
Free cash flow to the firm showed a similar pattern to operating cash flow, albeit with a slightly more pronounced fluctuation. FCFF started at $1,552 million in 2019 and increased steadily to $1,898 million in 2020 and $1,959 million in 2021. A notable decline occurred in 2022, with FCFF dropping to $1,535 million, which is the lowest figure for the period except for 2019. The following year, 2023, saw a recovery to $1,878 million. Despite the dip in 2022, FCFF in 2023 was higher than in any year before 2020, indicating overall growth of approximately 21% from 2019 to 2023.
Comparison and Insights
Both net cash provided by operating activities and free cash flow to the firm followed a broadly similar trajectory, characterized by steady growth through 2021, a decline in 2022, and a recovery in 2023. The decline in 2022 may suggest a temporary operational or investment-related challenge during that year. The subsequent recovery points to a strong return to cash-generating capacity. The gap between operating cash flow and FCFF narrowed slightly in some years, which may imply changes in capital expenditures or working capital management. Overall, the financial data reflect resilient cash flow performance with evidence of cyclical influences.

Interest Paid, Net of Tax

Zoetis Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid during the period for interest, net of capitalized interest, before tax
Less: Cash paid during the period for interest, net of capitalized interest, tax2
Cash paid during the period for interest, net of capitalized interest, net of tax
Interest Costs Capitalized, Net of Tax
Capitalized interest expense, before tax
Less: Capitalized interest expense, tax3
Capitalized interest expense, net of tax

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 2023 Calculation
Cash paid during the period for interest, net of capitalized interest, tax = Cash paid during the period for interest, net of capitalized interest × EITR
= × =

3 2023 Calculation
Capitalized interest expense, tax = Capitalized interest expense × EITR
= × =

The financial data reveals notable trends in the effective income tax rate, cash paid for interest, and capitalized interest expense over the five-year period examined.

Effective Income Tax Rate (EITR) %

The effective income tax rate demonstrated a gradual upward trend from 2019 to 2023. Starting at 16.7% in 2019, the rate increased modestly to 18% in 2020 and further to 18.2% in 2021. A more pronounced rise occurred in 2022, reaching 20.5%, with a slight decline to 20.3% in 2023. Overall, the rate increased by approximately 3.6 percentage points across the period, indicating a steady increase in the company's tax burden or effective tax obligations.

Cash Paid During the Period for Interest, Net of Capitalized Interest, Net of Tax (US$ in millions)

The cash outflows for interest payments, adjusted for capitalized interest and tax effects, showed moderate fluctuations over the five years. Beginning at $206 million in 2019, the figure saw a slight increase to $211 million in 2020, followed by a minor decrease to $207 million in 2021. The amount reduced further to $192 million in 2022 before rising again to $235 million in 2023. This pattern indicates variability in interest costs or financing activities, with the most significant increase observed in the final year.

Capitalized Interest Expense, Net of Tax (US$ in millions)

Capitalized interest expense exhibited a consistent upward trend throughout the period. Starting at $11 million in 2019, the expense increased steadily to $14 million in 2020, $16 million in 2021, and $17 million in 2022. The highest amount was recorded in 2023, at $22 million. This gradual increase suggests expanding capital projects or investments in assets requiring capitalization of interest costs, reflecting growing investment activities over time.


Enterprise Value to FCFF Ratio, Current

Zoetis Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2023-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Zoetis Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 See details »

3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.

The analyzed data reveals fluctuations in both enterprise value and free cash flow to the firm over the five-year period ending in 2023. The enterprise value exhibited an overall increasing trend from 2019 through 2021, rising from approximately US$73.4 billion to nearly US$96.4 billion. However, this was followed by a notable decline in 2022 to about US$83.98 billion, before a moderate recovery to US$88.54 billion in 2023.

Free cash flow to the firm (FCFF) demonstrated a generally positive trend with some variability. It increased steadily from US$1.55 billion in 2019 to US$1.96 billion in 2021, then decreased to US$1.54 billion in 2022, before rebounding to US$1.88 billion in 2023. This pattern indicates some volatility in cash generation capacity during this period, with a dip corresponding to the decline in enterprise value during the same year.

The EV/FCFF ratio, which measures the valuation of the company relative to its cash generation ability, reflected these changes through fluctuations. The ratio decreased from 47.27 in 2019 to 43.54 in 2020, suggesting improved valuation relative to cash flow. Yet, it rose sharply to 49.22 in 2021 and further increased to 54.71 in 2022, indicating that enterprise value outpaced free cash flow during this period, potentially signaling higher valuation multiples or decreased cash flow efficiency. By 2023, the ratio decreased again to 47.16, signaling a partial correction towards previous valuation levels relative to cash flow.

In summary, the data points to a phase of growth in enterprise value and cash flow up to 2021, followed by a period of decline and recovery, with valuation metrics fluctuating in response to these changes. The interplay between enterprise value and free cash flow suggests periods of relative overvaluation and normalization in the later years.